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Abstract
Alzheimer’s Disease (AD), the most common form of dementia, is a chronic neurodegenerative disease. The HECT
domain and ankyrin repeat containing E3 ubiquitin protein
ligase 1 (HACE1) gene is expressed in human brain and
may play a role in the pathogenesis of neurodegenerative
disorders. Till now, no previous study has reported the association of the HACE1 gene with the risk and Age at Onset
(AAO) of AD; while few studies have checked the proportional hazards assumption in the survival analysis of AAO
of AD using Cox proportional hazards model. In this study,
we examined the associations of 14 Single Nucleotide Polymorphisms (SNPs) in the HACE1 gene with the risk and the
AAO of AD using 791 AD patients and 782 controls. Multiple
logistic regression model identified one SNP (rs9499937
with p = 1.8 × 10-3) to be associated with the risk of AD. For
survival analysis of AAO, both classic Cox regression model
and Bayesian survival analysis using the Cox proportional
hazards model were applied to examine the association of
each SNP with the AAO. The Hazards Ratio (HR) with its
95% Confidence Interval (CI) was estimated. Survival analysis using the classic Cox regression model showed that 4
SNPs were significantly associated with the AAO (top SNP
rs9499937 with HR = 1.33, 95% CI = 1.13-1.57, p = 5.0 ×
10-4). Bayesian Cox regression model showed similar but a

slightly stronger associations (top SNP rs9499937 with HR
= 1.34, 95% CI = 1.11-1.55) compared with the classic Cox
regression model. Using an independent family-based sample, one SNP rs9486018 was associated with the risk of
AD (p = 0.0323) and the T-T-G haplotype from rs9786015,
rs9486018 and rs4079063 showed associations with both
the risk and AAO of AD (p = 2.27 × 10-3 and 0.0487, respectively). The findings of this study provide first evidence that
several genetic variants in the HACE1 gene were associated with the risk and AAO of AD.
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Introduction
Alzheimer’s Disease (AD) is a chronic neurodegenerative disease [1]. It is estimated that, in 2010, about 4.7
million people in the United States (US) aged 65 years or
older live with AD, and this number is projected to rise
to 13.8 million, a nearly three-fold increase, by 2050 [2].
Weuve et al. [3] estimated the number of adults (aged
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≥ 65 years) with AD in each US state and the District
of Columbia (DC) and found that the number of older
adults (aged ≥ 65 years) with AD in the US ranged from
5.1 (Alaska) to 530 million (California) in 2010; while in
2010, older adults with AD dementia comprised a median of 1.6% of a given state’s total population; whereas
by 2025, throughout the US, this proportion will keep
increasing by nearly one-third on average [3]. The prevalence was estimated to be about 3.12% in 2012 for older adults (≥ 60 years) in the US using the Nationwide Inpatient Sample (NIS) 2002-2012 [4]. A meta-analysis estimated the prevalence for the combined population of
African-Americans and Caucasians aged 65-90 in 2013
was 5.7% in the US; the prevalence for African-Americans aged 65-90 years was 8.6%, compared to 5.5% for
Caucasians [5]. Globally, 26.6 million people (0.40% of
the world population) suffered from AD in 2006 and it
was predicted to affect 1 in 85 people by 2050 [6]. A
recent meta-analysis showed that the prevalence of AD
in Europe was 5.05% for adult (aged ≥ 50 years) (3.31%
for males and 7.13% females) [7]. Increasing evidence
suggests that autophagy may play a central role in AD
[8,9]. The genetic heritability of AD ranges from 49% to
79% based on reviews of twin and family studies [10]. In
addition to the risk, the Age at Onset (AAO) of AD has a
genetic component with heritability about 42% [11,12].
The HECT domain and ankyrin repeat containing E3
ubiquitin protein ligase 1 (HACE1) gene (also known as
KIAA1320) is located at 6q16.3 [13-15]. The HACE1 is
expressed in brain, heart, lung, kidney, testis, and ovary [13,15]. Several studies have implicated that HACE1
is a candidate chromosome 6q21 tumor suppressor
gene involved in multiple cancers [16-18]. Recently, it
has been reported that HACE1 gene may play a role in
neurodegeneration [19] and autophagy pathway [20];
while HACE1 mutations are involved in an autosomal
recessive neurodevelopmental disorder [21], and glutamine addiction [22]. A Genome-Wide Association Study
(GWAS) identified five Single-Nucleotide Polymorphisms (SNPs) (rs17065302, rs11759010, rs6927608,
rs4946645 and rs4245525) within the HACE1 gene
associated with equol-producing phenotype such as
blood pressure, which may implicate HACE1 in intestinal immune responses [23]. Another GWAS identified 5
SNPs (rs4336470. rs9404576, rs4079063, rs24996663,
and rs2499667) in HACE1 associated with neuroblastoma susceptibility [24]; while in a replication study,
rs4336470 showed moderate association (p < 0.05) with
risk of neuroblastoma [25]. More recently, it has been
reported that the five above SNPs in the HACE1 gene
may have a weak combined effect (p = 0.065) on neuroblastoma risk in Southern Chinese children [26]. Thus
we hypothesized that HACE1 genetic variants may be in
association with AD development.
To our best knowledge, no study has focused on the
association of the HACE1 gene with the risk and AAO
of AD. Even though the Cox proportional hazards model
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has been used to detect genetic associations with the
AAO of AD [27-29], the proportional hazards assumption may be violated and they might not be carefully
checked. Bayesian methods have been widely used recently in genetic association studies and provide alternative ways to traditional statistical methods [30-32]. In
this study, we explored the association of HACE1 with
the AAO of AD by using a Bayesian proportional hazards
model in a population-based sample and then a family-based sample for replication.

Subjects and Methods
Study population
791 patients with AD and 782 controls with complete
genotype and phenotype information in a Canadian
sample were selected from the Multi-Site Collaborative
Study for Genotype-Phenotype Associations in Alzheimer's disease and the longitudinal follow-up of Genotype-Phenotype Associations in Alzheimer's disease and
the Neuroimaging component of Genotype-Phenotype
Associations in Alzheimer's disease-Study Accession:
phs000219.v1.p1. Covariates include sex and age. The
details about these subjects were described in previous
studies [27,33]. Genotyping was conducted using the
Affymetrix technique. The genotypes of 14 SNPs within
the HACE1 gene were available in this data.
A family-based study (1266 AD cases and their relatives, 1070 individuals with the AAO values) were
available from the National Institute on Aging - Late
Onset Alzheimer's Disease (NIA-LOAD) Family Study:
Genome-Wide Association Study for Susceptibility Loci
- Study Accession: phs000168.v1.p1. Genotyping by the
Center for Inherited Disease Research (CIDR) was performed using the Illumina Infinium II assay protocol.
The details about the sample of subjects were described
elsewhere [34]. There are 28 SNPs within the HACE1
gene in this family-based sample.

Statistical analysis
Descriptive statistics and genotype quality control:
Descriptive statistics were used to characterize participants’ sex, age and the AAO of AD stratified by AD case
and control status [29,35]. Hardy-Weinberg Equilibrium (HWE) was tested for all SNPs using the controls by
HAPLOVIEW software [36]. Then, Minor Allele Frequency (MAF) was determined for each SNP. Pair wise Linkage Disequilibrium (LD) statistics (r2) among SNPs were
assessed using the European sample from the HapMap
dataset (http://hapmap.ncbi.nlm.nih.gov/) and the
founders in the family study.
Multiple logistic and linear regression models in
PLINK software: Multiple logistic regression analysis of
each SNP with the risk of AD as a binary outcome, adjusted for sex and age, was performed using PLINK [37];
while the asymptotic p-values were obtained and the
Odds Ratio (OR) and 95% Confident Interval (CI) were
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estimated. The parallel procedure was performed for
the multiple linear regression analysis of each SNP with
the AAO of AD as a continuous outcome. Bonferroni
correction (α = 0.05/14 = 3.57 × 10-3) was used to deal
with the multiple comparison issue [38].
Bayesian Cox proportional hazards model in PROC
PHREG: The Cox proportional hazards model (1) or Cox
regression model [39] is widely used in the analysis of
time-to-event data [40-42].

=
h(t | x) h0 ( t ) exp ( β1SNPk + β 2 Sex + β3 Age )

(1)

where h(t / x) is the hazard at time t for a subject
(AAO for this study), h0 ( t ) is the baseline hazard function. The Hazard Ratio (HR) is defined as the ratio of the
predicated hazard function under two different values
of a predictor variable. The PHREG procedure in SAS fits
the Cox model by maximizing the partial likelihood function. Both the graphical and numerical methods [43]
were used to check the proportional hazards assumption in the ASSESS option of PROC PHREG. The ASSESS
option plots the cumulative score residuals against time
for each independent variable; while the RESAMPLE option computes the p-value of a Kolmogorov-type supremum test based on a sample of 1,000 simulated residual
patterns. A significant p-value indicates a poor fit.
The Akaike Information Criterion (AIC) (2) was used
as a measure of better fit among candidate models
[44,45].

{

}

AIC = − 2ln p ( x | θˆ) + 2k

(2)

where x is the random variable, is the maximum
likelihood estimate, and k is the number of parameters.
A smaller AIC generally indicates a better fit.
Bayesian statistics is an extension of Bayes theorem,
which can be written as (3)

P (θ Y ) =

P (Y θ ) P (θ )

(3)

P (Y )

where θ is the parameter of interest, Y is the observed evidence, P(Y) is the marginal probability, P(Y|θ)
is the likelihood function, P(θ) is the prior, and P(θ|Y)
is the posterior probability [32]. Bayesian Cox regression can be requested by using the BAYES statement in
the PHREG procedure. Summary statistics (Mean, Standard Deviation, the Highest Posterior Density (HPD) and
Credible Intervals, and Correlation Matrix) were com-

puted for each of the parameters. Trace plots, posterior
density plots, and autocorrelation function plots were
also provided [32]. For Bayesian survival analysis of the
AAO of AD, the normal prior was chosen for the coefficients and the Deviance Information Criteria (DIC) was
available instead of AIC. DIC is intended as a generalization of AIC [46]. A measure of effective numbers of
parameters is defined as pD in (4), where pD is the posterior mean deviance minus the deviance measured at the
posterior mean of the parameters.

{ ( )}

pD =
E  −2ln { p ( x | θ ) } + 2ln p x | θˆ

(4)

Then DIC is defined analagously to AIC as in (5). Models with smaller DIC are better supported by the data.

{ ( )}

DIC = -2ln p x θˆ + pD

(5)

The PHREG procedure in SAS was used to fit the Cox
model. Multiple Cox regression model analysis, adjusted
for sex and age, was conducted to examine association
of each SNP with the AAO of AD. Descriptive statistics
and Cox regression analysis were performed with SAS
v.9.4 (SAS Institute, Cary, NC, USA).
Family-based study: A family-based association
analysis for AD was performed using PBAT version 3.6.7
[47]. For the risk of AD, the Family‐Based Association
Test using Generalized Estimating Equations (FBAT-GEE)
was used [48]; while for the AAO, FBAT-Wilcoxon statistics were employed [49]. The AAO values for healthy
siblings were censored and age at entry into the study
was used. Haplotype analysis was conducted in 2 or
3-SNP sliding window.

Results
Descriptive statistics and genotype quality control
The demographic characteristics of the subjects are
detailed in Table 1. The mean AAO for cases was 76.4
and 72.3 years, respectively, in the NIA and Canadian
samples, respectively. All 14 SNPs had MAF > 5% and
were in HWE in the controls (p > 0.05); while 1 of 28
SNPs with HWE < 0.10-4 in the family sample was removed for further analysis.

Multiple linear and logistic regression analyses using
PLINK
We found that one SNP was associated with the risk
of AD (rs9499937 with p = 1.8 × 10-3) and four SNPs were

Table 1: Descriptive characteristics of cases and controls.
Variable
Sample size (n)
Mean of age at onset (years ± SD)
Median of age at onset (years)
Range of age at onset (years)
Mean age at entry (years ± SD)
Median age at entry (years)
Range of age at entry (years)

Family study (NIA sample)
Patients
Controls
1266
1279
76.4 (± 6.7)
77
50-98
75.5 (± 8.1)
75
42 - 103

Ke-Sheng et al. Int J Clin Biostat Biom 2017, 3:014

Case-control study (Canadian sample)
Patients
Controls
791
782
72.3 (± 8.5)
73
40-97
77.6 (± 8.6)
73.4 (± 7.9)
79
79
43 - 100
48 - 94
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associated with the AAO of AD (rs7746856, rs6941988,
rs9499937 and rs7770002 with p = 3.09 × 10-2, 3.88 ×
10-3, 7.39 × 10-4, and 3.14 × 10-2, respectively) (Table 2).
Interestingly, the same SNP rs9499937 showed associations with both the risk and AAO of AD and the results
remained significant after Bonferroni correction (p <
3.57 × 10-3).

premum test results based on 1,000 simulations for all
the covariates were not significant (p > 0.05), suggesting
the proportional hazards assumption was valid for all
the variables in the Canadian sample.

Supremum test for proportional hazards assumption

The classic Cox model showed that four SNPs were
associated with the AAO of AD (the CT genotype of the
top SNP rs9499937 with HR = 1.33, 95% CI = 1.13-1.57,
p = 5.0 × 10-4). The HRs based on the Bayesian survival
analyses revealed similar but a slightly stronger associations compared with the non-Bayesian analyses results (Table 3). The DIC for the four SNPs were similar
to those of AIC. The trace plot, posterior density plot,
and autocorrelation function plot based on Bayesian

Figure 1 and Figure 2 display the observed standardized score process with 20 simulated realizations from
the null distribution for rs9499937 CC and CT genotypes, respectively. The plots showed that the observed
process was atypical compared to the simulated realizations and revealed proportional hazards for the two
genotypes compared with TT. The Kolmogorov-type su-

Classic Bayesian Cox proportional hazards model using PROC PHREG

Table 2: SNPs associated with the risk and/or age at onset of AD (p < 0.05).
SNP
rs7746856
rs6941988
rs9499937
rs7770002

Position
105253053
105253349
105273953
105280138

Allelea
A
C
T
A

MAFb
0.47
0.47
0.19
0.47

HWEc
0.787
0.84
0.649
0.96

OR-ADd
0.92 (0.79 - 1.06)
0.92 (0.79 - 1.06)
0.73 (0.60 - 0.89)
0.92 (0.80 - 1.07)

p-ADe
0.246
0.239
1.80 × 10-3
0.268

β-AAOf
-0.367 (-0.70, -0.034)
-0.351 (-0.68, -0.019)
-0.79 (-1.25, -0.34)
-0.366 (-0.70, -0.033)

p-AAOg
0.0309
0.00388
7.39 × 10-4
0.0314

Minor allele; bMinor allele frequency; cHardy-Weinberg equilibrium test p-value; dOdds ratio based on logistic regression; ep-value
based on logistic regression; fRegression coefficient for Age at Onset (AAO) based on multiple linear regression; gp-value based
on linear regression.

a

Checking Proportional Hazards Assumption for rs9499937C_C
Observed Path and First 20 Simulated Paths

Standardized Score Process

2

0

-2

Pr > MaxAbsVal: 0.8240
(1000 Simulations)

-4

40

50

60

70

80

90

100

AAO
Figure 1: Explore plot for checking proportional hazards assumption for rs9499937C_C gentoype compared with rs9499937T_T
genotype.
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Checking Proportional Hazards Assumption for rs9499937C_T
Observed Path and First 20 Simulated Paths

Standardized Score Process

4

2

0

-2
Pr > MaxAbsVal: 0.7370
(1000 Simulations)
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Figure 2: Explore plot for checking proportional hazards assumption for rs9499937C_T compared with rs9499937T_T.
Table 3: SNPs associated with the age at onset of AD using PROC PHREG (p < 0.05).
SNP
rs7746856

rs6941988

rs9499937

rs7770002

GTa
C-C
A-A
A-G
T-T
C-C
C-T
C-C
C-T
T-T
A-G
A‑C
C-C

HRb

pc

AICd
7622.19

1.28 (1.04 - 1.57)
1.02 (0.87 - 1.20)

0.0208
0.82

1.27 (1.03 - 1.56)
1.01 (0.85 - 1.18)

0.026
0.959

1.33 (1.13 - 1.57)
1.35 (0.80 - 2.27)

5.0 × 10-4
0.266

1.27 (1.03 - 1.57)
1.01 (0.86 - 1.20)

0.0239
0.864

HRe

HPDf

1.28
1.02

1.02 - 1.56
0.86 - 1.19

1.27
1.01

1.02 - 1.54
0.85 - 1.18

1.34
1.35

1.11 - 1.55
0.68 - 2.06

1.28
1.02

1.02 - 1.55
0.85 - 1.19

7622.24

DICg
7622.21

7622.32

7616.16

7616.17

7622.37

7622.34

Tested genotype comparing with the reference; bHazards Ratio (HR) for the tested genotype based on classic Cox regression
analysis using PROC PHREG; cp-value for the tested genotype based on classic Cox regression analysis; dAkaike Information
Criterion (AIC) value based on classic Cox regression analysis; eHR for the tested genotype based on Bayesian Cox regression
analysis; fLower and upper 95% Highest Posterior Density (HPD) of HR based on Bayesian Cox regression analysis; gDeviance
Information Criteria (DIC) value based on Bayesian Cox regression analysis.
a

analysis (Figure 3) indicated that the Markov chain had
stabilized with good mixing for rs9499937. The posterior density plot, which estimates the posterior marginal distributions for the four regression coefficients,
showed a smooth and unimodal shape for the posterior
marginal distribution (Figure 4).

Family-based association analysis
We observed one SNP associated with the risk of AD
(rs9486018 with p = 0.0323) by using FBAT-GEE analysis in the family-based study. The T-A haplotype from
rs6937432 and rs6940552 revealed mostly significant
associations with the risk (p = 9.7 × 10-4). The T-T haploKe-Sheng et al. Int J Clin Biostat Biom 2017, 3:014

type from rs9786015 and rs9486018 and the T-G haplotype from rs9486018 and rs4079063 showed significant association with the risk (p = 1.56 × 10-3 and 4.46
× 10-3, respectively) (Table 4). Using the FBAT-Wilcoxon
test, the C-C haplotype from rs6937026 and rs6946640
revealed mostly significant associations with the AAO
(p = 0.0223). The C-A-G and C-C-A haplotype from
rs6437026, rs4946640 and rs6910034 showed associations with the AAO (p = 0.0274 and 0.0225, respectively). The T-T-G haplotype from rs9786015, rs9486018
and rs4079063 showed associations with both the risk
(p = 2.27 × 10-3) and the AAO (p = 0.0487).
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Diagnostics for rs9499937C_T
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Figure 3: Trace plot, autocorrelation function plot, and posterior density plot for rs9499937.
Table 4: Haplotype analysis of the risk and age at onset of AD in the family sample.
SNPs

Haplotypea

Frequencyb

Fam#c

p-valued

C-C
C-T
T-A
C-T
T-T
T-G
T-T-G

0.01
0.02
0.01
0.02
0.06
0.07
0.04

37
41
37
60
101
120
54

0.00144
0.00355
0.00097
0.0147
0.00156
0.00446
0.00227

C-C
C-A-G
C-C-A
T-T-A
T-T-G

0.23
0.51
0.16
0.01
0.04

166
156
100
22
46

0.0223
0.0274
0.0225
0.0719
0.0487

Risk of AD
rs9404573
rs9499927
rs9404573
rs9499934
rs6937432
rs6940552
rs1378720
rs13198196
rs9486015
rs9486018
rs9486018
rs4079063
rs9486015
rs9486018
Age at onset of AD
rs6937026
rs4946640
rs6937026
rs4946640

rs6910034

rs9486015

rs4079063

rs9486018

rs4079063

Haplotype inferred from 2 or 3 SNPs; bHaplotype frequency; cFAM# refers to the number of informative families using an additive model;
p-value for the haplotype based on FBAT-GEE analysis for the risk or based on FBAT-Wilcoxon analysis for the age at onset.

a
d

The linkage disequilibrium structure of the HACE1
gene
Using the HapMap data, we identified one haplotype
block including the four SNPs associated AD and/or AAO
in the case-control study. Figure 5 shows the LD structure based on LD statistics (r2). Based on the rough rule of
thumb, values of r2 > 1/3 might indicate sufficiently strong
LD that can be used for a fine mapping [50]. The neuroblastoma associated rs4336470 [24,25] had moderate or
strong LD with three AAO associated SNPs (rs7746856,
rs6941988 and rs7770002 with r2 = 0.6, 0.6 and 0.71, respectively) and weak LD with the risk and the AAO - assoKe-Sheng et al. Int J Clin Biostat Biom 2017, 3:014

ciated SNP rs9499937 (r2 = 0.27). Furthermore, there was
strong LD observed between rs2499663 and three AAO
associated SNPs (rs7746856, rs6941988 and rs7770002
with r2 = 0.81, 0.81 and 0.93, respectively). Using the
founders in the family study, LD structure based on (r2)
was constructed for all 28 SNPs (Figure 6). The two neuroblastoma associated SNPs (rs4336470 and rs9404576)
[24,25] had moderate LD with SNPs (such as rs6910034,
rs9404573, rs9499934, rs696937432, rs9486015, and
rs4079063) which built AD and AAO associated haplotype; while another neuroblastoma associated SNPs
rs2499663 [24,25] had moderate or strong LD with SNPs
involved in AD and AAO associated haplotype.
• Page 6 of 11 •
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Posterior Density Plots
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Figure 4: The posterior density plots for the 4 regression coefficients.

Figure 5: Linkage disequilibrium structure (r2) within the HACE1 gene using the HapMap data (Dark area shows r2 = 1).

Discussion
In the present study we explored the association
of 14 HACE1 SNPs with the risk and AAO of AD using
a case-control study and identified one SNP associated with AD and four SNPs with the AAO of AD using
PLINK software. Interestingly, the same SNP rs9499937
showed associations with both the risk and AAO of AD.
Bayesian Cox regressions revealed similar but a slight-

Ke-Sheng et al. Int J Clin Biostat Biom 2017, 3:014

ly stronger associations with the AAO of AD. Using an
independent family-based sample, one SNP rs9486018
was associated with the risk of AD while haplotype analyses further revealed the associations with the risk and
AAO of AD. The findings of this study provide the first
evidence that several genetic variants in the HACE1
gene influenced the risk and the AAO of AD.
A previous study suggested that rs9391227 in the
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Figure 6: Linkage disequilibrium structure (r2) within the HACE1 gene of 28 SNPs in the family sample (Dark area shows r2 = 1).

HACE1 gene was associated with celiac disease involved
in the immune system and antigen presentation [51];
while another study revealed that five SNPs (rs17065302,
rs11759010, rs6927608, rs4946645 and rs4245525)
within HACE1 gene associated with equol-producing
phenotype such as blood pressure [23] which may implicate HACE1 in immune responses. However, rs9391227
[51] was not available in both the case-control and
family-based samples; while equol-producing phenotype associated five SNPs [23] were not associated with
the risk or the AAO of AD in the case-control study and
rs6927608 was not associated with the risk and AAO of
AD in both samples. However, rs9391227 had strong LD
with three AAO associated SNPs (rs7746856, rs6941988
and rs7770002 with r2 = 1.0, 1.0 and 0.87, respectively)
in the case-control study (Figure 5); whereas rs6927608
had weak LD with other SNPs (Figure 5 and Figure 6).
Previous studies have shown that AD is a chronic neurodegenerative disease while autophagy, immune and inflammatory processes are involved in the pathogenesis
of AD [1,8,9,52-56].
Previous epidemiology studies have suggested comorbidity of AD with certain cancers [57-59]; whereas
there may be an inverse link between cancer and AD
[59-61]. Recently, a meta-analysis of nine studies supports an association between AD and decreased cancer
risk [62]. However, the mechanism still remains unclear [60]. Several SNPs (such as rs4336470, rs9404576,
rs4079063, rs24996663, and rs2499667) in the HACE1
have been found to be associated with neuroblastoma susceptibility [24-26]. In the present study, the T-G
haplotype inferred from the rs9486018 and rs4079063
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was found to be associated with the risk of AD; while
the T-T-A haplotype inferred from the rs9486015,
rs9486018 and rs4079063 was found to be associated
with the AAO of AD in the family-based study (Table
4). Furthermore, four neuroblastoma associated SNPs
(rs4336470, rs9404576, rs4079063 and rs2499663) [2426] had moderate to strong LDs with SNPs which built
AD and AAO associated haplotypes (Figure 6). In addition, recently, it has been reported that HACE1 may play
a role in neurodevelopment and addiction [19,21,22].
Taken together, the above findings may suggest that
HACE1 gene may be involved in the pathogenesis of AD,
cancers and blood pressure; however, the mechanism
warrants further studies.
Several strengths of this study are worthy of noting.
The present study provides the first evidence of several
genetic variants within the HACE1 gene associated with
the risk and the AAO of AD using a case-control sample
and a family-based sample for replication. Furthermore,
we checked the proportional hazards assumption using
both the graphical and numerical methods for the Cox
proportional hazards model and found that the proportional hazards assumption was valid for the AAO of AD
data in the Canadian sample. In addition, we conducted
Bayesian survival analysis of genetic variants with the
AAO of AD. Bayesian method may provide an alternative approach to assessing and verifying associations
that alleviates the limitations of p-values at the cost
of some additional modeling and it has recently made
great inroads in genetic association studies [30]. Like
other research studies, some limitations also exist in this
study. First, due to different genotyping platforms, only
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two SNPs (rs6927608 and rs24999663) overlap in two
samples; therefore, our replication results in the family-based sample are gene-based rather than SNP-based.
Second, only one SNP rs9499937 was associated with
the risk and AAO of AD in the case-control study; while
one haplotype T-T-G was associated with the risk and
AAO of AD in the family-based study; which revealed
heterogeneity between risk and AAO of AD. In addition,
our current findings might be subject to type I error and
need to be replicated in future studies.
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To the best of our knowledge, this is the first candidate gene study which investigated the associations
of HACE1 SNPs with the risk of and the AAO of AD. The
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the risk of and AAO of AD.
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